NCT06946849
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +5 more
- Locations
-
- Zhongshan Hospital, Fudan University Shanghai, Shanghai Municipality, China
Clinical trial condition
Cirrhosis, Familial, with Pulmonary Hypertension
Explore clinical trials studying Cirrhosis, Familial, with Pulmonary Hypertension. Study availability and eligibility vary by location and protocol.
30 public trials
14 recruiting studies
Cirrhosis, Familial, with Pulmonary Hypertension trial results
Not Yet Recruiting
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
NCT06648525
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +5 more
- Locations
-
- Harbin Medical University Harbin, Heilongjiang, China
NCT07479264
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +5 more
- Locations
-
- The First Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong, China
NCT07225452
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +10 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT07224737
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +14 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT07304388
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +5 more
- Locations
-
- Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China
NCT07153783
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +19 more
- Locations
-
- Shengjing Hospital of China Medical University Shenyang, Liaoning, China
Active, Not Recruiting
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
NCT07658586
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +13 more
- Locations
-
- Guangxi Medical University First Affiliated Hospital Nanning, Guangxi, China
Active, Not Recruiting
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
NCT07646717
- Conditions
- Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +5 more
- Locations
-
- Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin Municipality, China
Active, Not Recruiting
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316
- Conditions
- Adenocarcinoma, Advanced Solid Tumors, Carcinoma, +15 more
- Locations
-
- Stanford Cancer Institute Palo Alto, California, United States
- Mayo Clinic Jacksonville Jacksonville, Florida, United States
- Moffitt Cancer Center Tampa, Florida, United States
- University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States